12-month effect of middle ear pressure therapy with the EFET01 device for intractable definite Meniere's disease and delayed endolymphatic hydrops after certification by the public health insurance system in Japan.

MLA

Nakazato, Akira, et al. “12-Month Effect of Middle Ear Pressure Therapy with the EFET01 Device for Intractable Definite Meniere’s Disease and Delayed Endolymphatic Hydrops after Certification by the Public Health Insurance System in Japan.” Acta Oto-Laryngologica, vol. 142, no. 6, June 2022, pp. 491–98. EBSCOhost, https://doi.org/10.1080/00016489.2022.2085325.

APA

Nakazato, A., Takakura, H., Ueda, N., Do, T. A., Takeda, N., Watanabe, Y., & Shojaku, H. (2022). 12-month effect of middle ear pressure therapy with the EFET01 device for intractable definite Meniere’s disease and delayed endolymphatic hydrops after certification by the public health insurance system in Japan. Acta Oto-Laryngologica, 142(6), 491–498. https://doi.org/10.1080/00016489.2022.2085325

Chicago

Nakazato, Akira, Hiromasa Takakura, Naoko Ueda, Tram Anh Do, Noriaki Takeda, Yukio Watanabe, and Hideo Shojaku. 2022. “12-Month Effect of Middle Ear Pressure Therapy with the EFET01 Device for Intractable Definite Meniere’s Disease and Delayed Endolymphatic Hydrops after Certification by the Public Health Insurance System in Japan.” Acta Oto-Laryngologica 142 (6): 491–98. doi:10.1080/00016489.2022.2085325.